Recent work has identified genetic mutations that can serve as biomarkers for diagnosing and prognosticating prostate cancer, such as the fusion of Transmembrane Serine Protease 2 (TMPRSSS2) and E26 Transformation-Specific (ETS) family genes, MYC amplification, and alterations in Phosphatase and Tensin Homolog (PTEN) and Tumor Protein 53 (TP53) [6]. The gene discussed is TP53; the disease is prostate carcinoma.